Metraipolis › archive › dc_a8df7e910365

Novel Competitive, Nonpeptidic, SARS-CoV‑2 Mpro Inhibitors with Improved Solubility — Europe PMC PMID:42157831

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42157831
DOI
10.1021/acsmedchemlett.6c00041
License (as archived)
solo-consultazione
Archived
2026-11-02T17:35:53.483Z
SHA-256 of the archived text
ce6cf63eeb5ab920859adf6423f03bcdaa8e4e6041a451d4dfd5eb53194368c4
Stable URL of this page
https://metraipolis.com/documento/dc_a8df7e910365

How to cite

Novel Competitive, Nonpeptidic, SARS-CoV‑2 Mpro Inhibitors with Improved Solubility — Europe PMC PMID:42157831 — Europe PMC (en), https://europepmc.org/article/MED/42157831 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a8df7e910365 (Metraipolis archive dc_a8df7e910365, sha256 ce6cf63eeb5ab920859adf6423f03bcdaa8e4e6041a451d4dfd5eb53194368c4)
BibTeX
@misc{dca8df7e910365,
  title = {Novel Competitive, Nonpeptidic, SARS-CoV‑2 Mpro Inhibitors with Improved Solubility — Europe PMC PMID:42157831},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42157831},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a8df7e910365; sha256 ce6cf63eeb5ab920859adf6423f03bcdaa8e4e6041a451d4dfd5eb53194368c4},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42157831. Agents can read the archived copy with the MCP tool read_document.